MediLink Therapeutics specializes in the development of antibody-drug conjugates (ADCs) with a focus on creating innovative technologies that address unmet clinical needs in oncology. The company has established a unique technology platform known as TMALIN (Tumor-Microenvironment-Activable-LINker), which aims to overcome the limitations of traditional ADCs. This platform enhances the therapeutic efficacy of ADCs by enabling them to remain effective regardless of the antibody's endocytosis capability, thereby broadening the selection of antibodies. Additionally, TMALIN technology improves the accumulation of the drug payload in tumor tissues, leading to a higher therapeutic index and a strong bystander effect, which is particularly beneficial for tumors with low or absent antigen expression.

MediLink's product pipeline is robust, featuring several ADC candidates targeting various solid tumors, including those associated with B7H3, HER3, and C-MET, among others. The company emphasizes the importance of independent intellectual property rights in its technology development, ensuring that its innovations are competitive on a global scale. By continuously upgrading its technologies and expanding into new disease areas, MediLink aims to provide better therapeutic options for patients worldwide, thereby enhancing the overall landscape of cancer treatment.

China

Medilink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and the latest generation of technologies and products. Founded in 2020, the company is dedicated to developing globally competitive conjugated drugs with a focus on therapeutic effect.

MediLink Therapeutics

Company Details